Analysts expect Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to post sales of $26.07 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Tandem Diabetes Care’s earnings, with the highest sales estimate coming in at $27.22 million and the lowest estimate coming in at $25.07 million. Tandem Diabetes Care posted sales of $12.29 million during the same quarter last year, which suggests a positive year over year growth rate of 112.1%. The company is expected to announce its next earnings results on Tuesday, November 7th.

On average, analysts expect that Tandem Diabetes Care will report full-year sales of $26.07 million for the current year, with estimates ranging from $99.70 million to $103.36 million. For the next fiscal year, analysts expect that the firm will post sales of $144.01 million per share, with estimates ranging from $138.59 million to $154.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, July 27th. The medical device company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.80) by $0.40. The company had revenue of $21.30 million during the quarter, compared to analyst estimates of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. Tandem Diabetes Care’s quarterly revenue was down 7.4% on a year-over-year basis. During the same period in the prior year, the company posted ($6.00) earnings per share.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a report on Thursday, September 28th. Wedbush restated an “outperform” rating and issued a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a report on Friday, October 6th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.31.

A number of large investors have recently bought and sold shares of TNDM. Russell Investments Group Ltd. bought a new stake in Tandem Diabetes Care in the 1st quarter worth approximately $360,000. Bank of America Corp DE grew its position in Tandem Diabetes Care by 88.6% in the 1st quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after purchasing an additional 404,452 shares during the period. Paulson & CO. Inc. bought a new stake in Tandem Diabetes Care in the 1st quarter worth approximately $600,000. Iguana Healthcare Management LLC grew its position in Tandem Diabetes Care by 33.3% in the 1st quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after purchasing an additional 25,000 shares during the period. Finally, Keybank National Association OH grew its position in Tandem Diabetes Care by 32.7% in the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after purchasing an additional 72,177 shares during the period. 36.64% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/13/26-07-million-in-sales-expected-for-tandem-diabetes-care-inc-tndm-this-quarter-2.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.